HepaticMD: Transforming Liver Disease Diagnostics with AI
HepaticMD, developed by Eri Osta, aims to leverage routine lab data to identify liver disease, particularly metabolic dysfunction–associated steatotic liver disease (MASLD). Growing concerns about MASLD, often linked to obesity and diabetes, inspired the creation of a transparent AI model that not only predicts fibrosis risk but also explains its reasoning. Using public data, Osta’s model analyzes liver enzymes, demographics, and more, yielding results comparable to existing noninvasive tools.
With support from Texas Health Catalyst, HepaticMD is transitioning to a practical application that integrates with electronic health records, improving patient risk assessment and potentially reducing unnecessary biopsies. This initiative is part of a broader movement in Austin, where collaboration between engineers, physicians, and data scientists is paving the way for innovative health solutions. As AI continues to reshape medicine, HepaticMD exemplifies a commitment to early detection and better care for underserved populations.